NEWS


Date:2022-06-28

Press Release: Sparking Synergy! CHO Pharma and StemCyte Combine Antibody with Homogenous Glycan and Cell Therapy to Develop New Cancer Therapy.

 

Press Release 2022.06.28

Press Release: Sparking Synergy! CHO Pharma and StemCyte Combine Antibody with Homogenous Glycan and Cell Therapy to Develop New Cancer Therapy.

A joint effort between CHO Pharma and StemCyte for the development of allogeneic cord blood immune cell preparations

For the first ever collaboration combing homogeneous antibody with regenerative medicine to combat cancers, CHO Pharma Inc. (6586) signed a MoU with StemCyte on June 28th, 2022 to develop allogeneic cord blood immune cell technology. Besides the development of homogenous specific allogeneic cell preparation, the partnership plans to delve into the field of tumor immunotherapy. Utilizing CHO Pharma Inc.’s world-leading glycan homogenization technology on antibody and immune cell, a new generation of immunotherapy can be developed.

With the world-class research capability on carbohydrate-specific antibodies and patented glycan homogenization platform technology, CHOptimaxTM, scientists at CHO Pharma Inc. have successfully homogenized immune cells such as NT cells, NKT cells and T cells for immunotherapy. With the unique advantage of accessing both public and private hybrid cord blood banks, StemCyte has collaborated with more than 350 medical centers in the world, including Duke University Medical Center, UCLA Medical Center, LinKou Chang Gung Memorial Hospital and National Taiwan University Hospital, and successfully saved more than 2200 patients in the past 20 years. The practical immunotherapy experience of StemCyte and the special glycoengineering platform of CHO Pharma Inc. will spark a synergy in this collaboration.

CHO Pharma Inc. expects the powerful cord blood bank of StemCyte will promote the applications of antibodies with homogenous glycans in the field of cell therapy.

StemCyte expects the collaboration with CHO Pharma Inc. will combine the strengths of both companies to sooner bring affordable cell therapy products to patients.

Moreover, both parties are planning to combine their clinical studies for CHO Pharma Inc.’s homogeneous antibody drugs and StemCyte’s cell therapy products.

CHO Pharma company website: http://www.chopharma.com

Press Release: CHO-H01 of CHO Pharma Won an Award of Excellence
Dr. Wu, the president of CHO Pharma, spoke about “The Distance between Academe and Industry” at 2022 NBRP (National Biotechnology Research Park) Demo Day